the identification of actionable mutations in lung cancer via ctdna
Published 2 years ago • 180 plays • Length 1:22Download video MP4
Download video MP3
Similar videos
-
12:26
the significance of biomarker testing in patient identification
-
2:42
blood samples for detecting actionable oncogenic mutations in lung cancer
-
4:31
emerging applications of liquid biopsy in non-small-cell lung cancer
-
4:18
optimizing biomarker testing and ensuring appropriate treatment of metastatic nsclc
-
2:34
biomarker testing
-
8:29
liquid vs. tissue biopsies to detect t790m mutations
-
4:35
the importance of biomarker testing: what is liquid biopsy? - targeted therapies in lung cancer 2023
-
7:30
tops levine cancer institute: guideline-recommended biomarker testing in early-stage nsclc
-
56:48
detection of therapeutically targetable mutations in nsclc:
-
45:34
2021 oneoncology | advancing precision oncology in the community | liquid biopsy
-
1:38
liquid biopsy testing in lung cancer
-
0:51
tissue and liquid biopsy concordance in detecting egfr mutations in nsclc
-
4:33
how does liquid biopsy work?
-
1:14:14
fine-tuning biomarker testing to identify and target ret fusions in nsclc
-
5:29
accelerating lung cancer diagnoses through liquid biopsy
-
3:27
introducing liquid biopsies in lung cancer: critical thinking
-
0:54
the importance of liquid biopsy for cancer patients.
-
43:20
2022 liquid biopsy eqa for lung cancer (egfr) webinar - 28th june 2023
-
9:39
how are we using liquid biopsy in nsclc?